Abstract
Targeting the interaction interface is an effective strategy to obtain programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-L1) nanobody blockers. To ......
小提示:本篇文献需要登录阅读全文,点击跳转登录